EDIT

Editas Medicine, Inc.

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Editas Medicine, Inc. (EDIT) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (A+); its weakest is Profitability (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
D-
Factor Score 0.7 / 5.0
Momentum
C+
Factor Score 2.8 / 5.0
Revisions
A+
Factor Score 5.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.5
EV / EBITDA -2.3
Rev Growth YoY 37.4%
Gross Margin -73.3%
Price Return 3M -11.8%
Price Return 12M 1.4%
Catalyst Signal 0.00
Market Cap $384.7M
TTM Revenue $49.8M
Price / Sales 7.7
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B- (3.0) C- (2.0) D- (0.7) C+ (2.8) A+ (5.0) C+ (2.7)
2026-11-04 B- (3.0) C+ (2.7) D+ (1.7) C+ (2.7) A+ (5.0) B- (3.0)
2026-10-28 B- (3.0) C+ (2.7) D+ (1.7) C (2.3) A+ (5.0) B- (2.9)
2026-10-21 B- (3.0) C+ (2.7) D+ (1.7) C (2.3) A+ (5.0) B- (2.9)
2026-10-14 B- (3.0) C+ (2.7) D+ (1.7) C- (2.0) A+ (5.0) B- (2.9)
Page 1 of 8
…